About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

148.95 +5.18 (+3.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals ↗
Via Chartmill
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash. 
Via Benzinga
News headline image
Is Amgen Stock Outperforming the Dow?
Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗
Gilead Sciences is buying Arcellx for $7.8 billion because it sees potential for more than $6 billion in sales for anito-cel by 2029. GILD stock slipped as ACLX soared. 
Via Investor's Business Daily
News headline image
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗
Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer. 
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
From Arcellx, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
News headline image
Where Gilead Sciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Peering Into Gilead Sciences Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
From Gilead Sciences, Inc.
Via Business Wire
News headline image
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call
Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures.... 
Via StockStory
Topics Earnings
News headline image
3 Hyped Up Stocks We Steer Clear Of
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
News headline image
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
3 Overrated Stocks That Concern Us
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.